SCHEMBL15467673

SCHEMBL15467673

O=C(N[C@]1(c2ccc(C(F)(F)F)cc2)CCOc2cccnc21)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.57
TLR7 Q9NYK1 2/20 0.40
PDE2A O00408 3/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TRPV1 Q8NER1 4/20 0.38
KIF11 P52732 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
MAPT P10636 1/20 0.37
CASP3 P42574 1/20 0.37
GALK1 P51570 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467675 1.00 TRPM8 (0.57) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15466948 0.94 TRPM8 (0.57) TRPM8TLR7PDE2ARAB9ATRPV1
SCHEMBL15466947 0.94 TRPM8 (0.57) TRPM8TLR7PDE2ARAB9ATRPV1
SCHEMBL15467541 0.92 TRPM8 (0.54) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467543 0.92 TRPM8 (0.54) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467312 0.92 TRPM8 (0.57) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467310 0.92 TRPM8 (0.57) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467561 0.92 TRPM8 (0.57) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467563 0.92 TRPM8 (0.57) TRPM8TLR7PDE2ANPC1RAB9A
SCHEMBL15467040 0.90 TRPM8 (0.54) TRPM8NPC1RAB9AHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US claimed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO claimed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US claimed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885TLR7 905/4885PDE2A 891/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885TLR7 905/4885PDE2A 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.